Cardiovascular Risk and Diseases in Patients With and Without Leptin-Melanocortin Pathway Variants
- PMID: 36549983
- PMCID: PMC10079551
- DOI: 10.1016/j.mayocp.2022.10.028
Cardiovascular Risk and Diseases in Patients With and Without Leptin-Melanocortin Pathway Variants
Abstract
Objective: To study differences in cardiovascular risk factors and diseases between patients with and without genetic variants in the leptin-melanocortin pathway.
Methods: A cross-sectional study of patients with a history of severe obesity genotyped in June 2019 as participants of the Mayo Clinic Biobank was conducted in March 2022 to assess differences in cardiovascular risk and diseases between carriers of a heterozygous variant in the leptin-melanocortin pathway and noncarriers. Cardiovascular risk factors included hypertension, diabetes, dyslipidemia, and smoking. Cardiovascular disease includes coronary artery disease, peripheral artery disease, and cerebrovascular accidents. Patients with a history of bariatric surgery were excluded. We used logistic regression models to estimate the odds ratio and 95% CI, adjusting for age, body mass index (BMI), and sex.
Results: Among a total of 168 carriers (8%; 121 [72%] female; mean [SD] age, 65.1 [14.9] years; BMI, 44.0 [7.4] kg/m2) and 2039 noncarriers (92%; 1446 [71%] female; mean [SD] age, 64.9 [14.4] years; BMI, 42.9 [6.6] kg/m2), carriers had higher prevalence odds of hypertension (odds ratio, 3.26; 95% CI, 2.31 to 4.61; P<.001) and reported higher number of cardiovascular risk factors compared with noncarriers (2.4 [1.1] vs 2.0 [1.1]; P<.001). There were no significant differences in the adjusted odds associated with diabetes, dyslipidemia, smoking, or cardiovascular disease.
Conclusion: Despite having similar body weight and BMI, carriers of heterozygous variants in the leptin-melanocortin pathway had higher rates of hypertension than noncarriers. These findings point to an association between hypertension and leptin-melanocortin pathway variants.
Copyright © 2022 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Leptin-Melanocortin pathway variants and gastric emptying in patients with obesity.Neurogastroenterol Motil. 2024 May;36(5):e14764. doi: 10.1111/nmo.14764. Epub 2024 Feb 15. Neurogastroenterol Motil. 2024. PMID: 38361111 Free PMC article.
-
Effects of Heterozygous Variants in the Leptin-Melanocortin Pathway on Roux-en-Y Gastric Bypass Outcomes: a 15-Year Case-Control Study.Obes Surg. 2022 Aug;32(8):2632-2640. doi: 10.1007/s11695-022-06122-9. Epub 2022 Jun 3. Obes Surg. 2022. PMID: 35654930 Free PMC article.
-
Effects of Heterozygous Variants in the Leptin-Melanocortin Pathway on Transoral Outlet Reduction After Roux-en-Y Gastric Bypass: A Case-Control Study and Review of Literature.Obes Surg. 2023 Apr;33(4):1284-1288. doi: 10.1007/s11695-023-06462-0. Epub 2023 Jan 28. Obes Surg. 2023. PMID: 36708466 Review.
-
Dyslipidemia and its associated factors among community adults located in Shangcheng district, Zhejiang province.Sci Rep. 2024 Feb 21;14(1):4268. doi: 10.1038/s41598-024-54953-6. Sci Rep. 2024. PMID: 38383535 Free PMC article.
-
A comprehensive review of genetic causes of obesity.World J Pediatr. 2024 Jan;20(1):26-39. doi: 10.1007/s12519-023-00757-z. Epub 2023 Sep 19. World J Pediatr. 2024. PMID: 37725322 Review.
Cited by
-
Type 2 Diabetes Remission in Patients with Heterozygous Variants in the Leptin-Melanocortin Pathway after Roux-en-Y Gastric Bypass: A Matched Case-Control Study.Obes Surg. 2023 Nov;33(11):3502-3509. doi: 10.1007/s11695-023-06859-x. Epub 2023 Oct 6. Obes Surg. 2023. PMID: 37798511
-
The association between microvascular and macrovascular diseases and diabetes remission after bariatric surgery.Surg Endosc. 2024 Apr;38(4):1835-1843. doi: 10.1007/s00464-024-10687-0. Epub 2024 Feb 2. Surg Endosc. 2024. PMID: 38305895
-
Precision medicine for obesity: current evidence and insights for personalization of obesity pharmacotherapy.Int J Obes (Lond). 2025 Mar;49(3):452-463. doi: 10.1038/s41366-024-01599-z. Epub 2024 Aug 10. Int J Obes (Lond). 2025. PMID: 39127792 Review.
-
Leptin-Melanocortin pathway variants and gastric emptying in patients with obesity.Neurogastroenterol Motil. 2024 May;36(5):e14764. doi: 10.1111/nmo.14764. Epub 2024 Feb 15. Neurogastroenterol Motil. 2024. PMID: 38361111 Free PMC article.
References
-
- Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. New England Journal of Medicine 2017; 376(3): 254–66. - PubMed
-
- Abarca-Gómez L, Abdeen ZA, Hamid ZA, et al. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128· 9 million children, adolescents, and adults. The lancet 2017; 390(10113): 2627–42. - PMC - PubMed
-
- Van Gaal LF, Mertens IL, Christophe E. Mechanisms linking obesity with cardiovascular disease. Nature 2006; 444(7121): 875–80. - PubMed
-
- Eckel RH, Kahn R, Robertson RM, Rizza RA. Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Circulation 2006; 113(25): 2943–6. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical